Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases

GLP1R agonists are associated with a reduced risk of hypothyroidism and an increased risk of several autoimmune diseases.

• A 0.89 odds ratio suggests a reduced risk of hypothyroidism associated with GLP1R agonists.
• An increased risk of ulcerative colitis is indicated by an odds ratio of 1.48.
• Type 1 diabetes shows an odds ratio of 1.34, suggesting a higher risk with GLP1R agonists.
• Systemic lupus erythematosus has an odds ratio of 1.61, indicating an increased risk.
• Sarcoidosis is associated with GLP1R agonists, reflected in an odds ratio of 1.38.
• GLP1R agonists are linked to positive associations with 221 immune cell phenotypes and negative associations with 317 immune cell phenotypes.

AI simplified